Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: A global survey of physicians' practice

Figure 1 Distribution of countries of practice among the responding physicians.

Figure 2 Distribution of responses for the three strategy choice questions, each denoted by the title above. A: Continue 5ASA in a hospitalized steroid-treated paitent; B: Continue 5ASA in an out-patient staring oral steroids; C: Start de-novo 5ASA in a hospitalized steroid-treated patient. The gray bars denote the detailed distribution of by percentage of responses to each of the five multiple choice answers. The black bars denote the overall comparison between proportion of respondents endorsing the strategy (summed percentage of “Strongly agree” and “Tend to agree”) vs the proportion of respondents rejecting this strategy (summed percentage of “Tend to disagree” and “Strongly disagree”). 5ASA: 5-Aminosalycilates.

Figure 3 Distribution of responses for the three physician's perception questions, each denoted by the title above. A: 5ASA have very good safety profile; B: 5ASA are generally not expensive; C: 5ASA may have added benefit in combination with corticosteroids. The gray bars denote the detailed distribution by percentage of responses to each of the five multiple choice answers. The black bars denote the overall comparison between proportion of respondents agreeing to a contention (summed percentage of “Strongly agree” and “Tend to agree”) vs the proportion of respondents rejecting the contention (summed percentage of “Tend to disagree” and “Strongly disagree”). 5ASA: 5-Aminosalycilates.